Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822425 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31610887 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29908073 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29352152 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119400 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL1486209 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29477078 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30147576 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL2551441 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL27843401 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160177292-A1 | METHOD FOR SCREENING CATALYTIC PEPTIDES USING PHAGE DISPLAY TECHNOLOGY | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160177292-A1 | METHOD FOR SCREENING CATALYTIC PEPTIDES USING PHAGE DISPLAY TECHNOLOGY | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160039872-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2016-02-11 | — | — | US | disclosed |
| US-9257576-B2 | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-9174998-B2 | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20150175615-A1 | (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | PRISM PHARMA CO., LTD. (JP) | 2015-06-25 | — | — | US | disclosed |
| US-8969289-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130313669-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-11-28 | — | — | US | disclosed |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-1932853-A1 | Novel depsipeptides and process for preparing same | Cubist Pharmaceutical Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | CUBIST PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| EP-1814588-A2 | ANTIINFECTIVE LIPOPEPTIDES | Cubist Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006110185-A2 | ANTIINFECTIVE LIPOPEPTIDES | CUBIST PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1423414-A4 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARM INC (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1423414-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | Cubist Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030083240-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003014147-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083240-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | CASP3 3328/4885KMT2A 4116/4885MDM4 1268/4885 |
| US-20160039872-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PHKG1, ACP1 | CASP3 3193/4885KMT2A 2868/4885MDM4 384/4885 |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | DAO, BCAT1, BCAT2 | CASP3 3774/4885KMT2A 266/4885MDM4 1211/4885 |
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | CASP3 1022/4885KMT2A 4448/4885MDM4 1783/4885 |
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | CASP3 3328/4885KMT2A 4116/4885MDM4 1268/4885 |
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | VIP, DNPEP, PREP | CASP3 3328/4885KMT2A 4116/4885MDM4 1268/4885 |
| US-20150175615-A1 | (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | WNT1, WNT3A, WNT3 | CASP3 1013/4885KMT2A 1166/4885MDM4 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.